fda warning letters glp-1 compounders september 2025 news Beyond the Headlines: to GLP-1 Compounding: When Innovation May

Ann Intern Med

If burping and associated symptoms significantly impair quality of life or interfere with treatment adherence, patients should discuss this with their provider rather than discontinuing medication independently

There is no absolute medical contraindication between alcohol and semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), and the FDA prescribing information does not require complete abstinence

Addressing these gaps is critical to ensuring that GLP-1 RAs serve as a safe and effective intervention for womens metabolic health

Type 2 diabetes is usually accompanied by obesity and cardiovascular issues

Sjstrm L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjstrm CD, Sullivan M, Wedel H